- $93.09m
- $92.54m
- $27.64m
ImmuCell Q2 revenue rises on higher distributor volume, price realization
Brief: ImmuCell Corporation Q2 EPS USD 0.2
ImmuCell Q2 product sales rise 11.5% on strong US demand
ImmuCell Q1 sales, profit rise on seasonal demand; to moderate mid-year
Brief: ImmuCell Corporation Q1 EPS USD 0.21
Brief: ImmuCell, Norbrook Enter Settlement Deed On May 8, 2026 - SEC Filing
ImmuCell 2025 revenue rises 4.3%, net loss narrows
Brief: ImmuCell Corporation FY EPS USD -0.12
ImmuCell Q4 preliminary sales dip
Brief: ImmuCell Pauses Investment In Re-Tain
Animal health firm ImmuCell Q3 sales fall 8%, hurt by previous production interruptions
Brief: Immucell Announces Selection Of Its Next President And CEO
Brief: Immucell Corp - Extended $1 Million Line Of Credit With MCB
Brief: ImmuCell Corporation Q2 EPS USD 0.06
Brief: Immucell Embarks On CEO Succession Planning Process
Brief: ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
Brief: Immucell Hires Chief Financial Officer
Brief: ImmuCell Corp Entered Into At Market Offering Agreement With Craig-Hallum Capital Group LLC
Brief: Immucell Corp Says From Time To Time, It May Offer Up To $20 Million Of Common Stock, Warrants And Subscription Rights, In One Or More Transactions